TGFB1 and neoplasm: The concept behind bintrafusp alfa is that the anti-PD-L1 moiety targets drug delivery to the tumor, concentrating TGFβ depletion (and anti-PD-L1 activity) to sites of high PD-L1 in order to decrease any adverse side effects related to TGFβ blockade in normal tissue.